Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 20/20 | 0.80 |
| ▸ | CCR7 | P32248 | 4/20 | 0.71 |
| ▸ | CX3CR1 | P49238 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5998455 | 1.00 | CXCR2 (0.80) | CXCR2CCR7CX3CR1 | |
| SCHEMBL5498209 | 0.94 | CXCR2 (0.82) | CXCR2CCR7CX3CR1 | |
| SCHEMBL5493217 | 0.89 | CXCR2 (1.00) | CXCR2CCR7 | |
| SCHEMBL5498108 | 0.89 | CXCR2 (1.00) | CXCR2CCR7 | |
| SCHEMBL6360695 | 0.83 | CXCR2 (0.70) | CXCR2CCR7CX3CR1 | |
| SCHEMBL5499203 | 0.83 | CXCR2 (0.73) | CXCR2CCR7CX3CR1 | |
| SCHEMBL6352231 | 0.83 | CXCR2 (0.70) | CXCR2CCR7CX3CR1 | |
| SCHEMBL5495370 | 0.83 | CXCR2 (0.73) | CXCR2CCR7CX3CR1 | |
| SCHEMBL3856676 | 0.82 | CXCR2 (0.81) | CXCR2CCR7CX3CR1 | |
| SCHEMBL3853081 | 0.82 | CXCR2 (0.81) | CXCR2CCR7CX3CR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1328319-B1 | 7-AMINO-2-ALKYLTHIOPTERIDIN-4-YL-AMINES FOR THE TREATMENT OF CHEMOKINE-RELATED DISEASES | ASTRAZENECA AB (SE) | 2007-01-03 | — | — | EP | claimed |
| US-7071193-B2 | 7-amino-2-alkylthiopteridin-4-yl-amines for the treatment of chemokine-related diseases | ASTRAZENECA AB (SE) | 2006-07-04 | — | — | US | claimed |
| US-20040102447-A1 | 7-amino-2-alkylthiopteridin-4-yl-amines for the treatment of chemokine-related diseases | ASTRAZENECA AB (SE) | 2004-05-27 | — | — | US | claimed |
| EP-1328319-A1 | 7-AMINO-2-ALKYLTHIOPTERIDIN-4-YL-AMINES FOR THE TREATMENT OF CHEMOKINE-RELATED DISEASES | AstraZeneca AB (SE) | 2003-07-23 | — | — | EP | claimed |
| WO-2002032507-A1 | 7-AMINO-2-ALKYLTHIOPTERIDIN-4-YL-AMINES FOR THE TREATMENT OF CHEMOKINE-RELATED DISEASES | ASTRAZENECA AB (SE) | 2002-04-25 | — | — | WO | claimed |
| EP-1328319-B1 | 7-AMINO-2-ALKYLTHIOPTERIDIN-4-YL-AMINES FOR THE TREATMENT OF CHEMOKINE-RELATED DISEASES | ASTRAZENECA AB (SE) | 2007-01-03 | — | — | EP | disclosed |
| US-7071193-B2 | 7-amino-2-alkylthiopteridin-4-yl-amines for the treatment of chemokine-related diseases | ASTRAZENECA AB (SE) | 2006-07-04 | — | — | US | disclosed |
| US-20040102447-A1 | 7-amino-2-alkylthiopteridin-4-yl-amines for the treatment of chemokine-related diseases | ASTRAZENECA AB (SE) | 2004-05-27 | — | — | US | disclosed |
| EP-1328319-A1 | 7-AMINO-2-ALKYLTHIOPTERIDIN-4-YL-AMINES FOR THE TREATMENT OF CHEMOKINE-RELATED DISEASES | AstraZeneca AB (SE) | 2003-07-23 | — | — | EP | disclosed |
| WO-2002032507-A1 | 7-AMINO-2-ALKYLTHIOPTERIDIN-4-YL-AMINES FOR THE TREATMENT OF CHEMOKINE-RELATED DISEASES | ASTRAZENECA AB (SE) | 2002-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102447-A1 | 7-amino-2-alkylthiopteridin-4-yl-amines for the treatment of chemokine-related diseases | CXCR3, CXCR2, CCR2 | CXCR2 2/4885CCR7 4/4885CX3CR1 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.